Get ready for a groundbreaking development in the fight against obesity! 2026 is shaping up to be a pivotal year with the introduction of obesity pills from Novo Nordisk and Eli Lilly.
These innovative oral medications are set to revolutionize weight loss treatment, offering a more convenient and potentially cost-effective alternative to traditional injections. But here's where it gets controversial: while these pills may not be more potent than existing injections, health experts argue that expanding treatment options is a significant victory for patients.
Novo Nordisk and Eli Lilly are leading the charge, with their daily pills expected to reach U.S. patients in 2026. These pills are designed to address a range of needs, including those who fear needles or perceive their weight issues as less severe. And this is the part most people miss: these companies are already preparing for high demand, having experienced supply shortages with their injection-based treatments in recent years.
The Race to Market
Novo Nordisk is poised to beat its rival, with its oral semaglutide, the active ingredient in Wegovy and Mounjaro, expected to gain approval by the end of 2025. This means the pill version of Wegovy could hit the market early in 2026. Meanwhile, Eli Lilly is hot on their heels, with plans to file for approval of its oral GLP-1, orforglipron, by the end of the year. The FDA has granted a priority review voucher for this pill, potentially fast-tracking its review and approval process.
Cost and Accessibility
One of the most exciting aspects of these pills is their potential affordability. Under deals with President Donald Trump, both companies have committed to offering starting doses of their pills at $149 per month through the direct-to-consumer website TrumpRx, set to launch in January. This price point is significantly lower than the current list prices for their injection-based treatments, which can cost upwards of $1,000 per month before insurance.
Efficacy and the Competition
While it's challenging to directly compare the efficacy of these two drugs due to differences in clinical trial designs, some analysts suggest that Novo Nordisk's oral semaglutide may cause a greater level of weight loss based on available data. In Eli Lilly's ATTAIN-1 trial, the highest dose of its pill helped patients lose an average of 12.4% of their body weight at 72 weeks. In contrast, Novo Nordisk's oral semaglutide showed an average weight loss of up to 16.6% at 64 weeks, according to results presented in 2024. However, the slightly lower efficacy of Eli Lilly's pill may not deter patients, as it still offers a significant weight loss benefit.
Goldman analysts predict that Eli Lilly's pill will capture a 60% share of the daily oral segment of the market in 2030, while Novo Nordisk's oral semaglutide is expected to hold a 21% share. The remaining 19% is anticipated to go to other emerging pills, including those being developed by Viking Therapeutics, Structure Therapeutics, AstraZeneca, Roche, and Pfizer. These companies are expected to release more data on their experimental drugs next year, so stay tuned for the latest developments!
What do you think about these obesity pills? Are they a game-changer or just another treatment option? We'd love to hear your thoughts in the comments below!
